Biogen Reports Phase 2b Data for Cemiplimab in Thyroid disease

Biogen today announced Phase 2b results for cemiplimab in patients with thyroid disease. The study demonstrated that cemiplimab improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of thyroid disease and support the continued development of cemiplimab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.